^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) + Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
815P - A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification
Published date:
09/05/2022
Excerpt:
This is a single-arm, single-center, phase II clinical trial involving 37 pts (treatment-naive or refractory to standard therapy excluding Kit inhibitors and anti-PD-1/L1) with advanced melanoma harboring CKA….The ORR was 58.8% (95% CI: 32.7-84.9%) and DCR was 82.4% (95% CI: 56.6-96.2%). The mPFS was not reached (NR)....Imatinib mesylate/toripalimab combo was effective and well-tolerated in pts with advanced melanoma harboring c-kit aberrations.
Trial ID:
